This study focuses on people with Chronic Hepatitis B Virus Infection, a long-term viral infection that affects the liver. The research compares two medications: a new drug called ALG-000184 and an existing treatment called Tenofovir Disoproxil. The study aims to determine how well ALG-000184 works compared to Tenofovir Disoproxil in treating hepatitis B infection in adults who have not previously received treatment.
The study includes two groups of patients: those who test positive for a specific hepatitis B marker called HBeAg and those who test negative for it. Some participants will receive ALG-000184, while others will receive Tenofovir Disoproxil or placebo. The treatment period lasts for 48 weeks, during which researchers will monitor how well the medications control the amount of hepatitis B virus in the blood.
Throughout the study, participants will have regular check-ups to monitor their health. These check-ups include blood tests to measure virus levels, liver function tests, physical examinations, and heart monitoring with ECGs. The total study duration may extend up to 96 weeks to ensure proper evaluation of the treatment’s long-term effects and safety.
Bulgaria 
France 
Italy 
Romania 
Spain 